Edit
Multiplicom
http://www.multiplicom.com/Last activity: 25.03.2022
Active - Reference to Agilent Technologies
When we entered in a partnership with Multiplicom in 2011, the company already offered several diagnostic assays, including assays for breast cancer and cystic fibrosis. The company’s initial focus was on direct sales in Western Europe.
Multiplicom had also the ambition to develop a broad range of CE-labeled diagnostic assays that help patients and doctors to better understand the genetic basis of certain diseases and predispositions, such that personalized medicine can become a reality.
Multiplicom had also the ambition to develop a broad range of CE-labeled diagnostic assays that help patients and doctors to better understand the genetic basis of certain diseases and predispositions, such that personalized medicine can become a reality.
Employees: 51-200
Total raised: $10.33M
Founded date: 2011
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.02.2013 | - | $7.37M | - |
| 29.04.2011 | Series A | $2.97M | - |
Mentions in press and media 3
| Date | Title | Description |
| 25.03.2022 | Qbic establishes third fund | St-Denijs-Westrem, Belgium, 17 March 2022 – Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, announces the first close of its third fund at € 49 millio... |
| 11.02.2013 | Multiplicom Raises €5.5M | Multiplicom NV, a Niel, Belgium-based company that specializes in molecular diagnostics, raised €5.5m in funding. Backers included Flemish investment company PMV, RMM and Qbic ARKIV Fund and existing investors Gimv (Biotech Fonds Vlaanderen... |
| 29.04.2011 | Multiplicom Raises €2.0M in Series A Funding | Multiplicom, a Niel, Belgium-based molecular diagnostics startup, has raised €2.0m in its Series A funding round. Backers include Gimv, Gimv managed Biotechfonds Vlaanderen, VIB and University of Antwerp. Gimv and Gimv managed funds invest ... |